Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep;112(9):1382-1388.
doi: 10.1038/ajg.2017.215. Epub 2017 Aug 1.

Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians

Affiliations

Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians

Naga Chalasani et al. Am J Gastroenterol. 2017 Sep.

Abstract

Objectives: Idiosyncratic drug induced liver injury (DILI) is a rare but potentially serious liver disorder and a major cause of significant liver injury. Limited data exist on racial differences in DILI incidence, presentation, and course.

Methods: We compared the causative agents, clinical features, and outcomes of DILI among self-described African-Americans and non-Hispanic whites (Caucasians) enrolled in the DILIN Prospective Study. Individuals with definite, highly likely, or probable DILI enrolled between September 2004 and February 2016 were included in this analysis.

Results: 144 African-Americans and 841 Caucasian patients met the eligibility criteria. Causal medications varied by race: trimethoprim/sulfamethoxazole being the most common cause among African-Americans (7.6 vs. 3.6%) followed by methyldopa (4 vs. <1%), phenytoin (5 vs. <1%), isoniazid (4 vs. 4%), and amoxicillin/clavulanate (4.1 vs. 13.4%). The severity of illness, however, tended to be greater in African-Americans than Caucasians as determined by peak mean bilirubin (14.3 vs. 12.8 mg/dl), INR (1.9 vs. 1.6), and DILIN severity score (3.0 vs. 2.6). The frequency of severe cutaneous reactions was significantly higher in African-Americans (2.1 vs. 0.36% in Caucasians, P=0.048). African-Americans also had higher rates of hospitalization (76.7 vs. 57.6%, P<0.001), liver transplantation or liver related death by 6 months (10.2 vs. 5.8%, P=0.02 after controlling for selected covariates), and chronic DILI (24 vs. 16%, P=0.06).

Conclusions: The most common DILI causative agents differ between African-Americans and Caucasians. African-Americans are more likely to have severe cutaneous reactions and more severe liver injury leading to worse outcomes, including death and liver transplant.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: Dr. Chalasani has ongoing consulting activities (or had in preceding 12 months) with NuSirt, Abbvie, Eli Lilly, Afimmune (DS Biopharma), Tobira (Allergan), Madrigal, Shire, Cempra, Ardelyx, Gen Fit and Amarin. These consulting activities are generally in the areas of nonalcoholic fatty liver disease and drug hepatotoxicity. Dr. Chalasani receives research grant support from Intercept, Lilly, Gilead, Galectin Therapeutics and Cumberland where his institution receives the funding. Over the last decade, Dr. Chalasani has served as a paid consultant to more than 30 pharmaceutical companies and this outside activities have regularly been disclosed to his institutional authorities. Dr Reddy serves on ad hoc advisory board for Abbvie, Merck and Gilead. He has research support from Abbvie, Merck, Gilead, BMS, Janssen, and Conatus where his institution is the recipient of the funding. Dr. Fontana has received research support from BMS, Janssen, and Gilead and served as a consultant to Regulus. Drs. Barnhart, Gu, Stolz, Hayashi, Ahmad, Navarro, and Hoofnagle have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Study Population: Flow Diagram

References

    1. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug induced liver injury in general population. Gastroenterology. 2013;144:1419–1425. - PubMed
    1. Chalasani N, Bonkovsky HL, Fontana RJ, Vuppalanchi R, Hayashi PH, Navarro V, Reddy KR, Lee WM, Davern T, Barnhart H, Atolz A, Kleiner DE, Talwalkar J, Serrano J, Gu J, Watkins PB, Hoofnagle J. Drug-induced liver injury in the United States: A report of 899 events prospectively assessed. Gastroenterology. 2015;148:1340–1352.
    1. Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, et al. Persistent liver injury is more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450–1459. - PMC - PubMed
    1. Medina-Caliz I, Robles-Diaz M, Garcia-Munoz B, Stephens C, Ortega-Alonso A, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol. 2016;65:532–542. - PMC - PubMed
    1. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, et al. Drug induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55–68. - PMC - PubMed

MeSH terms